Fan Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fan Chen has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Anjing Zhao
Department of Oncology, The First Affiliated Hospital of Naval Military Medical University, Shanghai 200433, China
1 shared publication - Hong Yin
Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China
1 shared publication - Jie Diao
Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China
1 shared publication - Min Jiang
Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China
1 shared publication - Rufang Dong
Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China
1 shared publication - Suhua Xia
Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China
1 shared publication
Latest Publications
- 16 October 2026
- Published by Springer Nature in Clinical and Translational Oncology
- p. 1-15
Value and research advances of ctDNA in perioperative therapy for non-small cell lung cancer
Perioperative treatment plays an increasingly important role in improving outcomes for patients with resectable non-small cell lung cancer (NSCLC). Circulating tumor DNA (ctDNA) offers a new perspective for optimizing individualized perioperative management. This review systematically examines the core value of ctDNA in perioperative therapy for resectable NSCLC, encompassing its correlation with treatment response and pathological remission during the neoadjuvant phase, its utility as a dynamic monitor of treatment efficacy, and its emerging role in prognostic stratification and recurrence prediction in the postoperative setting. Importantly, while ctDNA demonstrates considerable promise for guiding individualized perioperative management, most applications remain investigational; we therefore distinguish between established correlative uses and prospective strategies currently under evaluation in clinical trials. It also addresses current technical challenges in ctDNA application, including limited sensitivity, false positives, lack of standardization, cost-effectiveness concerns, and difficulties in integration into clinical decision-making. Future prospective interventional studies are needed to validate ctDNA-guided treatment adjustments and to establish standardized protocols and multidisciplinary collaboration pathways, thereby facilitating the integration of ctDNA into the full course of perioperative management for NSCLC and enabling precise efficacy assessment, risk stratification, and individualized treatment decisions.
- 16 October 2026
- Published by Springer Nature in Clinical and Translational Oncology
- p. 1-15
Value and research advances of ctDNA in perioperative therapy for non-small cell lung cancer
Perioperative treatment plays an increasingly important role in improving outcomes for patients with resectable non-small cell lung cancer (NSCLC). Circulating tumor DNA (ctDNA) offers a new perspective for optimizing individualized perioperative management. This review systematically examines the core value of ctDNA in perioperative therapy for resectable NSCLC, encompassing its correlation with treatment response and pathological remission during the neoadjuvant phase, its utility as a dynamic monitor of treatment efficacy, and its emerging role in prognostic stratification and recurrence prediction in the postoperative setting. Importantly, while ctDNA demonstrates considerable promise for guiding individualized perioperative management, most applications remain investigational; we therefore distinguish between established correlative uses and prospective strategies currently under evaluation in clinical trials. It also addresses current technical challenges in ctDNA application, including limited sensitivity, false positives, lack of standardization, cost-effectiveness concerns, and difficulties in integration into clinical decision-making. Future prospective interventional studies are needed to validate ctDNA-guided treatment adjustments and to establish standardized protocols and multidisciplinary collaboration pathways, thereby facilitating the integration of ctDNA into the full course of perioperative management for NSCLC and enabling precise efficacy assessment, risk stratification, and individualized treatment decisions.
- Open Access
- 15 September 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (9) , 2268
Decoding TRIP13’s Role in Gastric Cancer: Implications for Prognosis and Immune Response
Background/Objectives: Gastric cancer (GC), a prevalent global malignancy and a leading cause of cancer-related mortality, has a poorly understood prognosis related to TRIP13 expression. TRIP13 has a recognized part in driving tumor progression across different cancer types, yet its precise role in GC remains beyond our full comprehension. Our study aimed to explore TRIP13’s prognostic value and function in GC patients. Methods: We extensively explored TRIP13’s influence on GC prognosis, functionality, and immune response by examining various cancer-related databases like UALCAN, GEPIA, GEO, and TIMER. Immunohistochemistry (IHC) staining was also conducted to assess the link between TRIM13 and GC patient survival. Results: TRIP13 expression levels were found to be significantly elevated in GC tissues compared to normal tissues through analysis of mRNA data from multiple public databases. IHC analysis exposed elevated TRIP13 protein levels in GC tissues and connected it with tumor depth. Prognostic evaluation demonstrated that GC patients exhibiting heightened TRIP13 expression endured a diminished overall survival rate. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses showed that genes related to TRIP13 are involved in processes such as the cell cycle and DNA repair. Additionally, TRIP13 expression was found to correlate with ferroptosis-related genes and may play a role in regulating ferroptosis. Immune cell infiltration analysis demonstrated that TRIP13 expression is negatively correlated with the infiltration of CD4+ T cells, CD8+ T cells, and B cells. Conclusions: TRIP13 emerges as a candidate independent prognostic indicator and a promising intervention point for GC treatment.
- 15 September 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (9) , 2268
Open AccessDecoding TRIP13’s Role in Gastric Cancer: Implications for Prognosis and Immune Response
Background/Objectives: Gastric cancer (GC), a prevalent global malignancy and a leading cause of cancer-related mortality, has a poorly understood prognosis related to TRIP13 expression. TRIP13 has a recognized part in driving tumor progression across different cancer types, yet its precise role in GC remains beyond our full comprehension. Our study aimed to explore TRIP13’s prognostic value and function in GC patients. Methods: We extensively explored TRIP13’s influence on GC prognosis, functionality, and immune response by examining various cancer-related databases like UALCAN, GEPIA, GEO, and TIMER. Immunohistochemistry (IHC) staining was also conducted to assess the link between TRIM13 and GC patient survival. Results: TRIP13 expression levels were found to be significantly elevated in GC tissues compared to normal tissues through analysis of mRNA data from multiple public databases. IHC analysis exposed elevated TRIP13 protein levels in GC tissues and connected it with tumor depth. Prognostic evaluation demonstrated that GC patients exhibiting heightened TRIP13 expression endured a diminished overall survival rate. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses showed that genes related to TRIP13 are involved in processes such as the cell cycle and DNA repair. Additionally, TRIP13 expression was found to correlate with ferroptosis-related genes and may play a role in regulating ferroptosis. Immune cell infiltration analysis demonstrated that TRIP13 expression is negatively correlated with the infiltration of CD4+ T cells, CD8+ T cells, and B cells. Conclusions: TRIP13 emerges as a candidate independent prognostic indicator and a promising intervention point for GC treatment.